Back to Search
WILLIAM WIERDA, M.D., PHD
M.D., PHD
Hematology & Oncology Physician
NPI: 1497848279IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
L3873(TX)
Education
OTHER
Class of 1993
Research & Publications (20)
Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia.
PMID 19074592·J Mol Diagn·2009
8-other
New prognostic factors in chronic lymphocytic leukemia.
PMID 19274038·Clin Adv Hematol Oncol·2009
8-other
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment.
PMID 19224852·J Clin Oncol·2009
8-other
Gene therapy and active immune therapy of hematologic malignancies.
PMID 17707840·Best Pract Res Clin Haematol·2007
6-review
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
PMID 17299097·Blood·2007
8-other
Initial therapy for patients with chronic lymphocytic leukemia.
PMID 16616067·Semin Oncol·2006
6-review
Current and investigational therapies for patients with CLL.
PMID 17124074·Hematology Am Soc Hematol Educ Program·2006
6-review
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
PMID 16353201·Cancer·2006
4-observational
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
PMID 15767647·J Clin Oncol·2005
8-other
Novel immune-based treatment strategies for chronic lymphocytic leukemia.
PMID 16155015·J Clin Oncol·2005
4-observational
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
PMID 12580959·Br J Haematol·2003
8-other
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
PMID 19646755·Leuk Res·2010
3-trial
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
PMID 19491390·Blood·2009
7-preclinical
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
PMID 19517462·Cancer·2009
8-other
Chronic lymphocytic leukemia: treatment options for patients with refractory disease.
PMID 19536902·Cancer·2009
6-review
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
PMID 19567878·Blood·2009
8-other
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
PMID 19637351·Cancer·2009
3-trial
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.
PMID 19414856·Blood·2009
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD
HOUSTON, TX 77030 - Phone
- (713) 792-3753
Quick Facts
- NPI
- 1497848279
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 33
- Publications
- 20
Are you this provider?
Claim Your Profile